Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin’s proprietary position in non-invasive frequency-based deep-brain neurostimulation Patent covers transcranial alternating current dynamic frequency stimulation methods for anxiety, depression and insomnia — three large and underserved markets central to Nexalin’s HALO™ Clarity and NeuroCare™ strategies HOUSTON, TX, June 04, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (“DIFS™”) of the brain, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia.” The newly issued patent is expected to provide U.S. intellectual property protection for Nexalin’s core dynamic frequency stimulation method through 2042, further strengthening the Company’s long-term competitive position in frequency-based deep-brain neurostimulation for anxiety, depression and insomnia. The patent expands Nexalin’s growing intellectual property portfolio and reinforces the Company’s leadership in non-invasive, frequency-based deep-brain neurostimulation. The patent covers methods involving transcranial alternating current stimulation using dynamic frequency stimulation designed for anxiety, depression and insomnia — three conditions that collectively represent a significant global unmet medical need and are central to Nexalin’s broader clinical, regulatory and commercial strategy. Nexalin believes the issuance of this patent and its existing patent portfolio are strategically important because they protect key elements of the Company’s proprietary approach to delivering dynamic frequency stimulation through non-invasive neuromodulation. Nexalin’s DIFS™ platform is designed to penetrate deeper brain structures associated with neuropsychiatric and neurological conditions. The Company’s proprietary DIFS™ treatment is designed to be administered and monitored through the Nexalin NeuroCare™ virtual clinic, which Nexalin believes represents a potential model for physician-supervised, drug-free, non-invasive mental health treatment for in-home use. “This patent represents another major milestone for Nexalin and strengthens the defensibility of our long-term platform strategy,” said Mark White, Chief Executive Officer of Nexalin Technology. “Although anxiety, depression and insomnia are among the most widespread and difficult-to-treat conditions in mental health, they are only the beginning for the Nexalin NeuroCare™ in-home clinic model. We believe our DIFS™ technology has the potential to create an entirely new category of non-invasive, deep-brain, drug-free treatment for patients who need alternatives beyond traditional medications and clinic-based treatment models.” Mr. White continued, “We believe this additional patent further validates the unique nature of our deep-brain frequency stimulation and reinforces the strategic importance of expanding our intellectual property portfolio. As we advance HALO™ Clarity, Nexalin NeuroCare™ and our AI-enabled virtual care platform with physician oversight, we believe strong patent protection across our platform will be critical to supporting clinical development, regulatory progress and long-term commercialization.” The patent builds on Nexalin’s broader intellectual property strategy covering applications of its DIFS™ technology across multiple mental health and neurological indications, including Alzheimer’s disease, traumatic brain injury (“TBI”), PTSD and other neurological conditions. Nexalin believes this expanding patent estate provides an important foundation for long-term shareholder value by supporting product differentiation, regulatory positioning and potential commercial exclusivity across large addressable markets. The issuance also comes as Nexalin continues advancing its next-generation HALO™ Clarity platform and Nexalin NeuroCare™ virtual clinic ecosystem. The Company’s strategy is to combine proprietary neurostimulation hardware, AI-enabled remote patient monitoring, treatment-compliance data capture, clinical workflow tools and physician oversight into an integrated model designed to improve access to care and support scalable deployment. “We believe the future of neurostimulation will be defined by three things: clinically meaningful technology, protected intellectual property and scalable care delivery,” added Mr. White. “This patent strengthens all three. It protects an important method of dynamic frequency stimulation while supporting our broader mission to make advanced brain-based treatment more accessible to patients through non-invasive, connected and physician-supervised care.” Nexalin’s DIFS™ technology is designed to deliver advanced frequency-based stimulation waveforms that e